[Edaily Reporter Kwon Oh Seok ] Shaperon Inc.(378800)has approved a 5-for-1 stock consolidation proposal, accelerating the restructuring of its financial structure and the global technology transfer of its core pipeline. Shaperon Inc. announced on the 7th that it had approved the 5-for-1 stock consolidation proposal as originally proposed at an extraordinary general meeting of shareholders held at its Seoul headquarters on the 6th.

With this decision, the par value per share will change from the current 500 won to 2,500 won, and the total number of issued shares will decrease from 46,243,031 to 9,248,606. The company plans to stabilize trading and share prices by maintaining an appropriate number of shares in circulation and will devote its full efforts to enhancing corporate value.
Now that Shaperon Inc. has finalized its financial and capital policy agenda, the company plans to focus its efforts on the commercialization and technology transfer of its key pipeline candidates that have entered the clinical trial phase. Its core pipeline includes treatments for △atopic dermatitis, △idiopathic pulmonary fibrosis, △dementia, △diabetic foot ulcers, and △acute respiratory distress syndrome (ARDS).
At the shareholders’ meeting held today, detailed results from Part 2 of the Phase 2b clinical trial for the atopic dermatitis treatment “NuGel” were presented, along with plans for subsequent clinical development (Phases 2c and 3) and a global technology transfer strategy. To date, NuGel has undergone a total of three clinical trials: one in South Korea and two in the United States (Parts 1 and 2).
The primary endpoints for the atopic dermatitis clinical trials are the “IGA-TS (Investigator Global Assessment-Treatment Success),” which evaluates the degree of skin improvement on a 0–4 scale, and the “EASI (Eczema Area and Severity Index),” which scores lesion severity on a scale of 1 to 72.
According to the company, based on the EASI score at Week 8 of the Phase 2b Part 2 clinical trial, no statistically significant difference was observed between the treatment group and the placebo group. However, based on the IGA-TS, results approaching statistical significance (p=0.053) were observed at Week 4, and the degree of improvement compared to the placebo group was higher than that of some competing drugs.
In the previously conducted Phase 2b Part 1 trial, the IGA-TS success rate in the NuGel group was approximately 50%, demonstrating superior results compared to the placebo group (11.1%). No serious drug-related adverse events were observed during the clinical trial, confirming its safety.
Shaperon Inc. also released the results of a Bayesian statistical analysis of the three NuGel clinical trials. According to the company’s feasibility analysis for proceeding to subsequent clinical trials, the probability of success for future clinical trials was estimated to be over 80% provided an adequate number of patients is secured.
A company official stated, “We are currently seeking a global partner to jointly conduct the follow-up clinical trial,” adding, “We will systematically organize our accumulated clinical data, statistical analysis materials, and follow-up clinical trial design strategies to actively leverage them for technology transfer, and we will spare no effort in achieving commercialization success for our other key pipeline candidates.”